Cardiff presents data underscoring ‘significant potential’ of onvansertib

Cardiff Oncology announced the presentation of five abstracts at the American Association for Cancer Research, AACR, taking place from April 5-10, in San Diego, California. In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer, mCRC, and other cancers. “Overall, the totality of our preclinical and clinical data we are presenting at AACR in mCRC is promising and provides scientific validation of our ongoing first-line RAS-mutated mCRC trial, where all patients have no prior exposure to bevacizumab, meaning they are bev naive,” said CEO Mark Erlander, Ph.D. “Furthermore, bev naive patients in our Phase 1b/2 KRAS-mutated mCRC trial were approximately 4 times (73 % vs 19%) more likely to achieve a clinical response compared to bev exposed patients in the dataset presented at AACR. This is consistent with the data we later generated from our randomized ONSEMBLE trial in RAS-mutated mCRC, which serves as a second independent data set reproducing the robust efficacy signal for onvansertib plus standard of care in bev naive patients. In addition, we are particularly encouraged by our RAS-mutated mCRC preclinical data highlighting onvansertib’s ability to inhibit activation of the hypoxia pathway via the regulation of HIF1alpha. We believe this mechanism acts complementary to bevacizumab, potentially providing an even greater reduction in tumor vascularization when the two agents are combined.”